Opko Health
About: OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Opko's diagnostics business includes a core genetic testing operation. It has a development and commercial supply pharmaceutical company, as well as a world supply-chain operation and holding company in Ireland. It also owns a specialty active pharmaceutical ingredients manufacturer in Israel. It operates in two segments Diagnostics and Pharmaceuticals.
Employees: 3,930
0
Funds holding %
of 6,831 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
22% more capital invested
Capital invested by funds: $230M [Q2] → $281M (+$50.2M) [Q3]
13% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 32
0.44% more ownership
Funds ownership: 26.43% [Q2] → 26.87% (+0.44%) [Q3]
0% more funds holding
Funds holding: 231 [Q2] → 232 (+1) [Q3]
14% less repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 63
30% less call options, than puts
Call options by funds: $16.8M | Put options by funds: $23.9M
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$2.25
49%
upside
Avg. target
$2.63
74%
upside
High target
$3
99%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Yi Chen 41% 1-year accuracy 64 / 158 met price target | 99%upside $3 | Buy Maintained | 8 Jan 2025 |
Barrington Research Michael Petusky 54% 1-year accuracy 38 / 71 met price target | 49%upside $2.25 | Outperform Maintained | 8 Nov 2024 |
Financial journalist opinion
Based on 3 articles about OPK published over the past 30 days
Neutral
GlobeNewsWire
3 weeks ago
OPKO Health to Present at the 43rd Annual J.P. Morgan Healthcare Conference
MIAMI, Jan. 09, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the 43r d Annual J.P. Morgan Healthcare Conference, being held January 13-16, 2025 at Westin St. Francis hotel in San Francisco. Management will be hosting one-on-one meetings with investors and will be presenting on Wednesday, January 15th at 3:00 p.m. Pacific time.
Positive
Zacks Investment Research
3 weeks ago
Here's Why You Should Retain OPKO Health Stock in Your Portfolio
OPK's growth is fueled by Rayaldee's success and accelerated clinical trials. However, stiff competition and overdependence on its lead product are concerns.
Positive
Zacks Investment Research
3 weeks ago
OPKO Health Announces Progress in EBV Vaccine Study, Stock Gains
OPK aims to advance a novel vaccine candidate for EBV infection, provide protective immunity to patients and prevent these diseases.
Positive
MarketBeat
1 month ago
3 Stocks That Wall Street Insiders Can't Stop Buying
Insider activity is hot in names like Vestis NYSE: VSTS, OPKO Health NASDAQ: OPK, and Greif, Inc. NYSE: GEF, and investors should take notice. From board members to CEOs, CFOs, and other corporate officers, insiders are buying these stocks en masse, signaling a higher-than-average conviction in the share price outlook.
Neutral
PRNewsWire
2 months ago
NextPlat to Showcase OPKO Healthcare Products at the 2024 China International Natural Health & Nutrition Expo
OPKO Healthcare's Veterinary Care Products to be Introduced at Asia's Largest Health and Nutrition Tradeshow Company Invited to Present at Special Event Hosted by U.S. Consulate General During the Expo COCONUT GROVE, Fla. , Nov. 18, 2024 /PRNewswire/ -- NextPlat Corp (NASDAQ: NXPL, NXPLW) ("NextPlat" or the "Company"), a global e-commerce provider, today announced that it is participating in the 2024 China International Natural Health & Nutrition Expo (NHNE), Asia's largest exhibition focused on the sales and marketing of health, nutrition and dietary supplement products, as the Company continues to ramp-up sales and promotional activities in China.
Neutral
PRNewsWire
2 months ago
NextPlat Reports $49.8 Million in Consolidated Revenue for the Nine Months Ended September 30, 2024, Representing a 136% Increase Over 2023 Results
Company Sees Initial Sales Momentum in China for OPKO Health Products as it Prepares for the Launch of its Florida Sunshine Brand of Vitamins and Supplements COCONUT GROVE, Fla. , Nov. 14, 2024 /PRNewswire/ -- NextPlat Corp (NASDAQ: NXPL, NXPLW) ("NextPlat" or the "Company"), a global e-Commerce provider, today announced results for its third fiscal quarter ended September 30, 2024 which includes the consolidation of the operations of its e-Commerce Operations with the results of its Healthcare Operations from Progressive Care LLC (formerly Progressive Care Inc., or "Progressive Care").
Neutral
Zacks Investment Research
2 months ago
OPK Stock Gains Following Q3 Earnings Beat, Gross Margin Contracts
Lower revenues from OPKO Health's products and services dampen its overall third-quarter 2024 performance.
Positive
Zacks Investment Research
2 months ago
Here's What Key Metrics Tell Us About OPKO Health (OPK) Q3 Earnings
Although the revenue and EPS for OPKO Health (OPK) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Neutral
Seeking Alpha
2 months ago
OPKO Health, Inc. (OPK) Q3 2024 Earnings Conference Call Transcript
OPKO Health, Inc. (NASDAQ:OPK ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Yvonne Briggs - Alliance Advisor, IR Phillip Frost - Chairman and CEO Elias Zerhouni - Vice Chairman, President Adam Logal - CFO Conference Call Participants Maury Raycroft - Jefferies Yi Chen - H.C. Wainwright Edward Tenthoff - Piper Sandler Michael Petusky - Barrington Research Operator Good day, and welcome to the OPKO Health Third Quarter of 2024 Financial Results Conference Call.
Positive
Zacks Investment Research
2 months ago
OPKO Health (OPK) Q3 Earnings Surpass Estimates
OPKO Health (OPK) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.10 per share. This compares to loss of $0.11 per share a year ago.
Charts implemented using Lightweight Charts™